US FDA approves GSK's Cervarix for prevention of HPV 16/18 cervical disease
This article was originally published in Scrip
Executive Summary
The US FDA on October 16th approved GlaxoSmithKline's vaccine Cervarix for prevention of cervical cancer and pre-cancerous lesions caused by human papillomavirus types 16 and 18 in women aged 10-25 years.